Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Jan 15, 2025 11:17am
118 Views
Post# 36405051

RE:RE:RE:RE:RE:RE:Today's News Release

RE:RE:RE:RE:RE:RE:Today's News Release

Reminder, just a few days ago they presented at the JP Morgan " investment" event.
numberring In the hundreds of pharma , big & small.
As well as potential pharma investors.
so, they hear a story. Of what is to come. Then a few days later a decent news release.
Lots of informed eyes & ears.
The news created a multitude of events.
Prior to today, as of nasdaq, there were 2.6 million shares sold short. 

in addition, the Nas is fully automated. Any standing buy or sell orders would be filled.
Saying all that 29 million shares , of which 28;were premarket, for a company that averages 1/10th of thst.
historically 1-2 million/ day for oncy iis a lot.
mutiple in/ out trades ? Could be. Short covering, strong possibility.
institutional buying ? also possible.
ATM selling into the market? Also possible.
New retail interest from the news & JP Morgan event..also possible.
The volume is very bizzar , nice choice of words.
gives us something to talk about.
My opinion, the volume is a combination of all the above.
premarket is a very strange & unpredictable world.
one other important point. The 29 million shares is 1/3 of the existing float.
meaning a lot of new people are on board. Or institutions.



 

<< Previous
Bullboard Posts
Next >>